In a recent TPD Searchlight workshop, participants delved into the realm of clinical insights surrounding TPD degraders currently undergoing clinical trials. Through the examination of two case studies, the workshop shed light on key approaches and considerations. It aimed to address critical questions, including the prediction of clinical responses based on pre-clinical data, a comparison between PROTACs and traditional small molecule drugs, the identification of unexpected effects during the transition from in vitro to in vivo, and the exploration of common characteristics among compounds in the clinical setting.
To gain comprehensive knowledge about the workshop proceedings, download the post-workshop summary using the button below. In this summary, you will discover the purpose of the workshop, meet the experts and participants involved, and gain an overview of the significant outputs and learnings from the session focused on lessons learnt from TPD degraders.